Shahla Rezaei

949 citations
31 papers · 601 indexed · h-index 10

Shahla Rezaei

31 papers receiving 577 citations

Peers

Shahla Rezaei
Comparison fields: 5 of 97
  • Infectious Diseases 173
  • Epidemiology 158
  • Endocrinology, Diabetes and Metabolism 138
  • Neurology 95
  • Molecular Biology 83
Replace Peyman Nowrouzi‐Sohrabi with:
Peyman Nowrouzi‐Sohrabi Iran
Maria Tsoumani Greece
Emmanouil Korakas Greece
Fatma Yılmaz Türkiye
Jasbinder Kaur India
Lulu Liu China
Gholamreza Daryabor Iran
Andrea Da Porto Italy
Ben Liu China
Manasvi Gupta United States
Shahla Rezaei relative to Peyman Nowrouzi‐Sohrabi Iran Peyman Nowrouzi‐Sohrabi's profile →
Citations per field
00.5×1.5×1.9×
Peyman Nowrouzi‐Sohrabi · 1×
Citations per year

Countries citing papers authored by Shahla Rezaei

Since Specialization
Citations

This map shows the geographic impact of Shahla Rezaei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shahla Rezaei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shahla Rezaei more than expected).

Fields of papers citing papers by Shahla Rezaei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shahla Rezaei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shahla Rezaei. The network helps show where Shahla Rezaei may publish in the future.

Co-authorship network of co-authors of Shahla Rezaei

This figure shows the co-authorship network connecting the top 25 collaborators of Shahla Rezaei. A scholar is included among the top collaborators of Shahla Rezaei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shahla Rezaei. Shahla Rezaei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 7
2 5
3 1
4 1
5 5
6 3
7 2
8 8
9 24
10 7
11 43
12 223
13 11
14 25
15 12
16 7
17 45
18 8
19 47
20 60

About Shahla Rezaei

Shahla Rezaei is a scholar working on Complementary and Manual Therapy, Endocrinology, Diabetes and Metabolism and Biological Psychiatry, having authored 31 papers that have together received 601 indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (5 papers), Diet, Metabolism, and Disease (4 papers) and Diabetes Treatment and Management (4 papers). The work is most often cited by research in Infectious Diseases (173 citations), Endocrinology, Diabetes and Metabolism (138 citations) and Neurology (95 citations). Shahla Rezaei has collaborated with scholars based in Iran, Netherlands and Australia. Frequent co-authors include Peyman Nowrouzi‐Sohrabi, Reza Tabrizi, Masoumeh Akhlaghi, Hamed Akbari, Seyyed Mohammad Amin Kashani, Kamran Bagheri Lankarani, Seyed Taghi Heydari, Fariba Ahmadizar, Maryam Gholamalizadeh and Saeid Doaei. Their work appears in journals such as European Journal of Pharmacology, British Journal Of Nutrition and Current Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026